Posted by Michael Wonder on 13 Dec 2020
Reimbursement from pharmaceutical companies decreases by 288 million
11 December 2020 - The rebate from side agreements between regions and pharmaceutical companies is estimated according to the forecast to amount to SEK 2,796 million in 2020.
This is a decrease of SEK 288 million compared with 2019. This is shown by the Swedish Dental and Pharmaceutical Benefits Agency, TLV's, forecast of savings from side agreements 2020.
The main reason for the reduction is that the reimbursement for the drug group hepatitis C is estimated to be significantly lower compared with 2019 when fewer patients have been treated.
